Octagon Therapeutics is focused on developing innovative treatments for patients suffering from autoimmune and inflammatory diseases by targeting immune checkpoints that are often disrupted in these conditions. Their approach involves restoring the function of specific checkpoint receptors on immune cells, which helps maintain healthy immune responses without compromising the immune system. By leveraging insights from the glycoproteome, Octagon aims to uncover critical biological mechanisms that drive disease, thereby enabling the development of therapies that can effectively address the underlying causes of autoimmune disorders.

The company has a robust pipeline of products, including CT50 and OCT102, which target specific immune pathways. CT50 works by restoring the function of Siglec-2, a checkpoint that regulates B cell responses, thereby selectively suppressing autoreactive B cells. Meanwhile, OCT102 is designed to inhibit the secretion of inflammatory cytokines from CD8+ T cells, which are known to contribute to various inflammatory diseases. Additionally, Octagon is engaged in a discovery program aimed at identifying immune cell populations involved in inflammatory and fibrotic processes, with a notable partnership with Novo Nordisk to explore treatments for cardiometabolic diseases. Their proprietary glycoproteome discovery engine further enhances their ability to develop targeted therapies by elucidating the role of glycans in immune pathology.

United States

Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.

Octagon Therapeutics

Company Details